Tag: Molbio Diagnostics

Health

Molbio & UE LifeSciences Partner to Expand iBreastExam Globally for Early Breast Cancer Detection

Tanisha Cardozo

Molbio Diagnostics has announced a strategic global collaboration with UE LifeSciences to expand the reach of iBreastExam, a radiation-free, painless, and FDA-cleared breast cancer screening device, to more than 50 countries across Asia, Africa, and beyond. This partnership represents a major step forward in making early detection accessible to millions of women who face barriers to traditional screening methods.

Breast cancer remains the leading cancer among women worldwide, and late detection is one of the most significant factors contributing to mortality. By combining Molbio’s extensive global distribution network with UE LifeSciences’ innovative technology, this collaboration aims to transform the landscape of breast cancer screening in low- and middle-income regions.

iBreastExam is a portable, battery-operated point-of-care device that can identify breast lumps in minutes without pain, radiation, or the need for specialized infrastructure. Using advanced sensor technology, it automates physical examination, ensuring accuracy without requiring interpretation from the user. With cloud-enabled storage for seamless follow-up, it is designed for use in primary healthcare settings, outreach programs, and mass screening campaigns, particularly in communities where access to mammograms is limited or non-existent.

Mihir Shah, Founder and CEO of UE LifeSciences, emphasized the importance of this initiative, highlighting that Molbio’s strong market presence and experienced team will help amplify their shared mission to improve women’s health outcomes globally. Molbio’s track record of delivering innovative diagnostic solutions, including the WHO-endorsed Truenat PCR platform, positions the company as a strong partner to scale the reach of iBreastExam.

The collaboration will focus on rolling out the device across India, Africa, the Middle East, CIS countries, the Philippines, Indonesia, and Vietnam, creating new opportunities for early intervention and saving countless lives through timely diagnosis.

This partnership is not just about technology—it is about bridging gaps in access to healthcare, empowering women, and ensuring that early detection of breast cancer is no longer a privilege, but a global reality.

Business

Molbio Diagnostics Files DRHP with SEBI: Plans ₹200 Crore Fresh Issue, Major Expansion Ahead

allycaralgoa

Molbio Diagnostics Limited, a Goa-based leader in point-of-care (POC) molecular diagnostics, has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for its much-anticipated Initial Public Offering (IPO).

The IPO will include a fresh issue of equity shares aggregating up to ₹200 crore and an Offer for Sale (OFS) of up to 1.25 crore equity shares by existing shareholders.

According to the DRHP, Molbio plans to utilize the net proceeds as follows:

  • ₹99.3 crore for infrastructure development including a state-of-the-art R&D facility, Center of Excellence, and office space.
  • ₹73.5 crore for purchase of plant, machinery, and equipment for its Goa and Visakhapatnam manufacturing units.
  • The remainder for general corporate purposes.

Molbio’s patented Truenat platform is recognized globally in over 100 countries as a breakthrough in rapid molecular diagnostics. Being portable and battery-operated, Truenat enables decentralized testing and provides results within an hour, making it crucial for diseases like tuberculosis, COVID-19, HIV, HPV, and Hepatitis B & C.

  • Incorporated in 2000, Molbio operates five manufacturing facilities across India — two in Goa, one in Visakhapatnam, and two in Bengaluru.
  • The Machohalli (Bengaluru) unit, operated by its subsidiary Prognosys Medical Systems, manufactures radiology products including ultraportable X-rays and C-arm systems.
  • As of March 31, 2025, the company’s annual installed capacity was 3,600 devices and 3.9 crore test kits.

In FY25, Molbio Diagnostics reported:

  • Revenue from operations: ₹1,020 crore (22% YoY growth)
  • Profit After Tax: ₹138.5 crore

The company’s promoters include Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, and Exxora Trading LLP.

The book-running lead managers for the IPO are Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India, and Motilal Oswal Investment Advisors.

With robust financials, a globally recognized platform, and plans for significant expansion, Molbio Diagnostics’ IPO is poised to be a landmark event in India’s healthcare and diagnostics sector.

Health

Molbio Diagnostics Empowers Philippines to Fast-Track TB Elimination with Truenat and Ultra-Portable X-ray Tech

Tanisha Cardozo

Tuberculosis (TB) continues to be one of the Philippines’ most pressing public health challenges, with nearly 190,000 cases going undetected each year. In a transformative move aligned with the UN goal to treat 2.1 million TB cases by 2027, the Philippines Department of Health has embraced Indian innovation to revolutionize its TB response.

At the forefront is the Truenat® platform, a WHO-endorsed, ICMR-approved molecular diagnostic solution developed by Goa-based Molbio Diagnostics. Designed for portability, accuracy, and speed, the Truenat® system supports rapid testing not just for TB, but for a wide array of infectious diseases, including HIV, HPV, and Hepatitis B & C.

Currently, 68 Truenat® devices are operational across the Philippines. A pilot on Bantayan Island yielded a staggering 1008% increase in TB detection — a powerful testament to the platform’s impact.

Geographic barriers, under-resourced labs, and limited rural access have long hindered TB diagnosis in the Philippines. Truenat®, alongside the newly approved PRORAD Atlas Ultraportable X-ray system, now makes it possible to deliver end-to-end screening, diagnosis, and treatment — even in the most isolated communities.

During an official visit to Molbio’s facility in India, Philippines Health Secretary Dr. Teodoro J Herbosa commended the partnership, calling it a “beacon of innovation” and highlighting the broader strategic alliance between the two nations. “Truenat® allows for swift and accurate TB screenings, enhancing our capacity to manage and eventually eliminate TB within our borders,” he said.

This healthcare collaboration reflects a growing Indo-Philippine partnership that now exceeds $3 billion in trade, spanning pharmaceuticals, medical technology, and beyond.

Molbio Diagnostics will further its engagement with the Philippines by hosting a panel at the 31st Philippine Coalition Against Tuberculosis (PhilCAT) Annual Convention in Manila on August 14–15, 2025.

The company’s broader mission continues through projects like a multi-country R2D2 TB Network study exploring tongue-swab molecular testing — a game-changer for TB detection among children and people with HIV/AIDS.

“By bringing diagnostics to the doorstep of underserved communities, we aim to close the TB care gap and help countries build stronger, more resilient health systems,” said Shiva Sriram, President of Molbio Diagnostics.

Social

Molbio Diagnostics Strengthens CSR Impact with New Therapy Units for Children with Disabilities in Goa

allycaralgoa

Goa, July 16: In a powerful stride toward inclusive healthcare, Molbio Diagnostics, the Goa-based global innovator behind the WHO-recognised Truenat PCR platform, has launched Occupational Therapy and Audiology Units at Aastha’s Centre of Excellence, marking a new milestone in the company’s CSR journey.

This latest initiative is designed to serve over 100 children with disabilities every year, providing professional assessments and regular therapy sessions to support the development of sensory, motor, and communication skills. The Audiology Unit will also address undiagnosed hearing impairments, one of the most overlooked developmental challenges in children.

The therapy units aim to bridge critical healthcare access gaps in Goa, especially for vulnerable families who often lack affordable therapeutic services. Molbio’s intervention is not just a donation — it’s a commitment to empowering children and families with the tools they need for a better quality of life.

The inauguration ceremony, set to take place at Aastha’s Centre in Goa, will see participation from local dignitaries, health professionals, and CSR leaders, underlining the significance of public-private partnerships in enabling long-term social change.

“At Molbio, we believe that access to quality healthcare is a right, not a privilege,” said a company spokesperson. “This initiative is about ensuring inclusivity and equity in care — especially for children who need it the most.”

As the company continues to set benchmarks in public health innovation, its CSR arm remains focused on sustainable and scalable solutions that leave a meaningful impact in the communities it serves.

Social

Molbio Diagnostics Donates Electric Garbage Vehicles to Sankhalim Municipal Council, Reinforcing Its Green Commitment

allycaralgoa

Sanquelim, Goa | June 5, 2025 — In a powerful step towards sustainable development and environmental stewardship, Molbio Diagnostics, a leader in healthcare innovation, has donated 10 electric garbage collection vehicles to the Sankhalim Municipal Council in Goa. This green initiative, launched in partnership with the Goa CSR Authority, reflects Molbio’s growing commitment to cleaner communities and climate-conscious solutions.

The formal handover ceremony took place today in the presence of Dr. Pramod P. Sawant, Chief Minister of Goa, underlining the state’s strong focus on embracing sustainable technologies in municipal services.

⚡ A Green Push for Goa’s Municipal Waste Management

The electric vehicles, designed for solid waste collection, will now serve across the Sankhali constituency, streamlining daily waste collection with zero emissions and low operational costs. By reducing reliance on diesel-fueled transport, the move is expected to save several lakhs annually in fuel expenses while simultaneously cutting down the carbon footprint of waste management operations.

This contribution is part of Goa’s larger vision under the Swachh Bharat Abhiyaan and ties into the Chief Minister’s sustainability agenda, which emphasizes non-polluting technologies and efficient civic systems.

🌿 Driving Sustainable Impact

Speaking at the event, Amol Lone, President & CFO of Molbio Diagnostics Ltd., emphasized the dual impact of the initiative:

“At Molbio, we believe innovation should serve both people and the planet. Clean surroundings have a direct impact on quality of life, and these electric vehicles are a small but meaningful step toward healthy living and a more sustainable future. We’re glad to play our part in shaping that future.”

The initiative aligns closely with Molbio’s CSR mission, which focuses on blending healthcare, technology, and environmental action to improve lives while protecting natural ecosystems.

🤝 Public-Private Synergy

The collaboration between Molbio Diagnostics and the Goa CSR Authority showcases the positive outcomes that result when private enterprises and public institutions align their resources and goals. The donated vehicles are expected to greatly enhance the Sankhalim Municipal Council’s capacity to:

  • Collect domestic waste more efficiently
  • Reduce emissions from daily municipal operations
  • Lower maintenance and fuel costs
  • Improve the overall cleanliness and hygiene of local neighborhoods

This marks a significant milestone in Goa’s green infrastructure journey, and further cements Molbio’s status as a socially responsible business leader.